12:35pm (EST)
The market is mixed after a higher open and then fell into negative territory as we head into the second half of trading. We could really see the action pick-up as we head towards the closing bell and if we trend higher the bulls will be feeling good over the weekend.
If the market can push through resistance today and then again on Monday we could see individual investors and those who haven’t believed the rally start to jump back in.
The narrow range we have been in over the past few weeks could lead to a big explosion to the upside and there are a lot of catalysts that can take us higher.
We are also aware that the market is also at a “double top” and there is a chance of a pullback but we can feel the momentum, folks.

Currently, the Dow is up 6 points to 10,618, the S&P 500 is flat at 1,150 while the Nasdaq is holding fort at 2,368.
No news, yet, on the FDA’s decision for Amylin Pharmaceuticals (AMLN, $20.41, down $0.78) diabetes drug Byetta but the company did mess up on an inspection. Talk about not dotting your “i’s” and crossing your “t’s”, the company had a manufacturing plant that wasn’t up to par when U.S. regulators paid the company a visit during a December inspection.
Geez, it almost makes us want to rush out and buy the March 15 puts (AQM100320P00015000, $0.80, up $0.10). We won’t take the trade because the company could still get some good news but there have been 8,500 contracts traded thus far.
Next week the March options expire and this usually brings added volatility so we wanted to update all of our trades early today. We have one open trade that is up 165% and we are sure our subscribers are eager to hear our thoughts.
We are getting ready to crank it up next week with 5-10 possible hot NEW trades and the profit opportunities look really good. You could make next week one to remember by adding some serious gains to your portfolio if you are ready to join us in the action. There will be risks and we will be looking at both calls and puts to play the volatility.
We will be back Sunday night with the Weekly Wrap and a complete review of this week’s action and a fresh outlook. We are at a pivot point and the battle between the bulls and bears next week could be a classic…













Moody’s Sours Bulls Mood
Monday, March 15th, 2010
1:20pm (EST)
The bears have started the week off by tugging on Superman’s cape, but they have done little damage up to this point. The are numerous headwinds the bulls are facing today, but it seems they are taking their time digesting all of the news just like we are.
The Dow is currently down 25 points to 10,599 while the S&P 500 is lower by 6 points to 1,144. The Nasdaq is down 17 to 2,350.
Moody’s (MDO, $28.22, down $0.04) said the risks are growing for some of the world’s largest triple-A-rated countries: Germany, France, the U.K. and the U.S.
And…?
Moody’s has gotten everything wrong, and we honestly don’t know why anyone would care what the firm has to say. They missed so many calls during the subprime and financial crisis that it’s hard to believe the company is still in business. Even harder to believe is the fact shares are trading near $30…
The Financial stocks are taking a hit as Washington pushes ahead this week on legislation to overhaul the our financial system. The bill is expected to ”curb” Wall Street’s influence over the Federal Reserve Bank of New York. It looks like Obama wants to have the final say on who runs the show in NY instead of the current board that includes representatives of member banks.
As far as economic news, the Federal Reserve Bank of New York’s Empire Manufacturing Survey came in at 22.86 this month from 24.91 in February. Wall Street had expected a reading of 24 for the month. Although manufacturing output was down the report said it is continuing to improve at a steady pace in March, including a rise in new orders and improvement in the labor markets.
Amylin Pharmaceuticals (AMLN, $22.89,up $2.63) is up over 13% after the FDA said it didn’t need more clinical data on its diabetes drug, Bydureon. However, the FDA did say they would like changes made to clarify the product labeling and asked questions about the drug’s manufacturing process.
We were more interested in shares of Alkermes (ALKS, $13.79, up $1.58) which is the company that enables the slow delivery of the drug. The stock has jumped 13% but the March 12.50 calls (QAL100320C00012500, $1.15, up $0.30) are up 35%. They have traded to a high of $1.75 which is where they opened.
If Amylin hadn’t blown its inspection on Friday, we may have swung the bat…
We think there is a chance the bulls wake up today as the market has come off its lows and overall we are still expecting a higher March. We have update the Members Area so let’s get to it…
Tags: Alkermes, ALKS, AMLN, Amylin Pharmaceuticals, MDO, Moody's, option picks, option signals, options alerts, stock options trading
Posted in Company Commentary, Market Commentary | Comments Off